Neuvivo is dedicated to creating therapeutics for the treatment of Amyotrophic Lateral Sclerosis (ALS) and other neurodegenerative diseases. We have developed a patented macrophage-targeted technology, NP001, that addresses chronic inflammation, a key factor in the progressive loss of motor function in ALS.

NP001 has received Orphan Drug and Fast Track designation by the FDA as it addresses a clear unmet medical need.   We are working to move this compound toward approval and delivering an effective and safe new treatment for ALS. 

Biotechnology

Health Care

Therapeutics

Neuvivo

Org chart

Teams

Offices

Similar companies